News

Drug Development Collaboration

BridgeBio Pharma Inks Licensing Deal With Bristol Myers Squibb Worth up to $905 Million

Edward Kim | Equities.com |

BMY will pay BBIO $90 million in upfront cash.


Innate Pharma Gets $50 Million From AstraZeneca as Monalizumab Phase 3 Lung Cancer Trial Begins

Edward Kim | Equities.com |

The AstraZeneca deal continues to be a good one for Innate Pharma, year after year.


Adagene Partners With Sanofi in Biobucks Deal Worth Up to $2.5 Billion

Edward Kim | Equities.com |

Sanofi will pay Adagene $17.5 million up front.


Sponsored Financial Content

Market Movers